Clinical trial
Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or…
NCT00408070 · UConn Health, Other · Terminated
Key facts
| NCT number | NCT00408070 |
|---|---|
| Title | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Official title | Phase 2 Study of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma |
| Lead sponsor | UConn Health, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Stage 3 Cancer, Stage 4 Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Carboplatin, Paclitaxel |
| Enrollment | 5 |
| Start date | Oct 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Dec 6, 2006 |
| Last update posted | Mar 8, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: